Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Biofrontera ( (BFRI) ).
On June 3, 2025, Biofrontera Inc. filed a supplement to its Proxy Statement to update stockholders on voting procedures for their 2025 Annual Meeting. The supplement clarifies that Proposals 2 and 3 are considered routine matters under NYSE rules, allowing brokers to vote on them without instructions from shareholders, contrary to previous disclosures. Stockholders are urged to review these changes and vote accordingly.
The most recent analyst rating on (BFRI) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.
Spark’s Take on BFRI Stock
According to Spark, TipRanks’ AI Analyst, BFRI is a Neutral.
Biofrontera’s overall stock score is driven by financial vulnerabilities, technical weaknesses, and valuation issues. Despite some operational improvements highlighted in the earnings call, compliance challenges with Nasdaq significantly impact the outlook.
To see Spark’s full report on BFRI stock, click here.
More about Biofrontera
Average Trading Volume: 114,746
Technical Sentiment Signal: Sell
Current Market Cap: $5.4M
For a thorough assessment of BFRI stock, go to TipRanks’ Stock Analysis page.